BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast
Reichman discusses BiondVax’s 2023 achievements, including the development of innovative NanoAbs in collaboration with the Max Planck Institute targeting interleukin-17 (IL-17) targeting diseases such as psoriasis Annual sales for current anti-interleukin-17 monoclonal antibodies now total about $7.5 billion annually – and BiondVax is positioned to penetrate this market with promising results Investor Brand Network (“IBN”) recently announced the release of its latest episode of The Bell2Bell Podcast, featuring Amir Reichman, CEO of BiondVax Pharmaceuticals (NASDAQ: BVXV). The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries – like BiondVax’s innovative platform technology using alpaca-derived nanosized…